Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise.
In June 2023, Novo Holdings announced the signing of a definitive agreement to acquire Paratek.
Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.
A lead product of the company, Nuzyra (omadacycline), is currently available in the US as a once-a-day oral and intravenous antibiotic.
The treatment is indicated for use in adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Paratek is currently carrying out a Phase IIb clinical trial of Nuzyra for nontuberculous mycobacterial (NTM) pulmonary disease.
The company also has a partnership agreement in place with Zai Lab for omadacycline’s development and marketing in greater China and retains all worldwide rights for ex-greater China markets.
Novo Holdings partner Aleks Engel said: “We are committed to maintaining Paratek’s leadership in reaching patients and delivering innovative products across the globe.
“We look forward to supporting the continued growth of Nuzyra, and the expansion of Paratek’s product portfolio, including the acquisition or licensing of other therapeutics in antibiotics and beyond.”
Novo Holdings is a holding and investment company that manages Novo Nordisk Foundation and healthcare investment firm Gurnet Point’s assets and wealth.